Hot Investor Mandate 1: Venture Capital Seeking Investment Opportunities in Healthcare, Automation/Robotics Companies and Relations to Healthcare

A venture capital firm with offices in USA, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Toronto-based Life Sciences Venture Capital Invests in Therapeutics, Medical Devices, Diagnostic Imaging and Healthcare IT

A Toronto-based life sciences venture capital firm with offices throughout USA and Canada manages over $250M and is currently investing from a new fund closed in 2017. The firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and Healthcare IT. The firm is looking for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: China-Based Investment Management Firm Seeking Equity Investment and Licensing Opportunities in China and the US

A investment management firm based in China manages multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries, including healthcare. The firm’s healthcare portfolio includes Chase Sun Pharmaceutical, Lisheng Pharma, Tasly Pharm, Furui Medical Science, Zhongxin Pharmaceutical, and Tianyao Medical Industry. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Japan-Based Corporate Venture Arm Invests in Early-Stage Companies in the Biotech Therapeutics, Medical Technology and Devices, Diagnostics, and Healthcare IT Sectors

A venture arm of a Japan-based corporate with offices in Japan, China, India, and Silicon Valley makes seed, venture, and growth stage investments in companies in the life sciences space as well as other spaces like IT and cleantech. The firm typically makes equity investments in the range of $3-5M per portfolio company.

The firm primarily invests in life science companies based in the USA, but due to the firm’s global presence, the firm can also invest in companies based in China, Japan, India, and Europe. The firm has no current mandate for the number of allocations it plans to make in the space and will evaluate relevant opportunities as they surface.

The firm invests in early-stage companies in the biotech therapeutics, medical technology and devices, diagnostics, and healthcare IT sectors. The firm is sector and indication agnostic.

The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Partnering: Transitioning Conferences from Information-Centric to Relationship-Centric

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation’s Redefining Early Stage Investments (RESI) conference is a partnering event that requires high touch on both the buy side (investors and pharma) and sell side (startup) constituents. To do partnering correctly takes a high human resource allocation; it is expensive to fund, and requires deep curation of a clientele database for each conference iteration. LSN has discovered that our database curation begets savvy list management, which in turn allows us to target constituents and provide them with customer support and training to use the partnering system efficiently. In today’s life science domain, conferences still lead as a place to make new business connections in addition to accessing the latest information on the advances in drugs, devices, diagnostics, and healthcare IT.

Informational-based life science conferences have worked for decades to successfully “break the profitability code”. Breaking the code means finding the precise point between internal resource output and maximum revenue gain, and balancing on it. The irony here is that if the conferences wish to be part of the industry’s new trend of relationship-based conferences with a strong partnering component, they will have to modify their view on resource allocation for partnering at their events. This may seem like a small issue that simply requires dedicating more resources to partnering, which causes a hit to the bottom line. However, it is actually a huge core issue that exposes an inherent dichotomy that must be traversed, or we will see a upheaval in the traditional conference market.

A lot of the information-based, super technical, scientific conferences that cater to academia and very early stage discoveries have found themselves in the crosshairs of big pharma and other large partners who are moving upstream to find technology that isn’t already identified and partnered up. This is another reason why these early stage scientific conferences are now in need of a partnering component, which will require higher capital spend and higher human resources to implement. This epiphany will go against the basic grain of the business philosophy of most of the conference providers. I will posit that if they don’t get partnering right, they will become vulnerable as there is a distinct and growing need from both buyers and sellers to build business connections at these conferences. The question is, can the conference providers change the lens on how they value their conferences?

The conference folks I talk to seem unconvinced that you really need a partnering effort that goes beyond a basic software application and a dedicated space at their venues. Indeed, it seems as if they are still trying to talk themselves into supporting partnering at all! Is this a fatal flaw?

Based on the 5 years of experience that I have garnered in the partnering conference marketplace, I will provide some of my insights. Great partnering is very hard to get right, it’s resource intensive and it is “high touch”. You do successful partnering by creating a consistent dialogue with your constituents. This entails focused marketing via newsletters promos, emails and phone canvassing. You need dedicated staff who reach out (yes, talk with!) and understand both the buy-side and sell-side needs of the clients. The staff’s job is to talk to the clients and understand their needs and keep a record of what the client needs, what technology they are interested in and who they are seeking to meet. If you initiate this compelling dialogue, it soon turns into a relationship, and having a direct relationship with your clients is the holy grail.

I also question whether the conference providers want great partnering or “me too” partnering? LSN’s style of interactive dialogue and relationship building through business development is very different than that of info-based conference organizations. LSN’s thesis is that we are NOT a conference company; we are a buyer seller matching platform with a conference, and that’s what gives RESI’s partnering platform its incredible power to forge new connections.

RESI San Francisco @ JPM Week – Medical Devices Panel Announcement

By Claire Jeong, Research Analyst, LSN

claire

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, “smarter” devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare.

If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:

  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan “Z” Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital

Impact Investors and Venture Philanthropists Explain How They View Impact Opportunities

By Lucy Parkinson, Director of Research, LSN

Nonprofits and foundations have long played a part in funding basic research into disease biology. However, it takes more financing and development resources for this valuable work to create new products that make an impact on patients. This has caused a trend in the philanthropic space toward investing in early stage life science ventures that have the power to transform treatment in a space of unmet need or to significantly improve health outcomes. Simultaneously, some financially-minded investors have seen the possibility of investing more meaningfully, and have chosen to put their wealth to work in venture funds that look for a ‘double bottom line’ – a good return on capital plus a positive result for the world.

At RESI San Francisco, this investment trend is showcased at the Venture Philanthropy and Impact Investment panel. This panel features both philanthropic organizations and for-profit investment funds, with focuses ranging from a rare disease with no cure to the broad goal of improving healthcare. We’re looking forward to what should be a wide-ranging discussion on how these investors find the right startup investing opportunities to fulfil their respective missions.

Moderated by John Reher, Managing Director – Brain Trust Accelerator Fund, the panelists are:

  • Debra Miller, Founder – CureDuchenne Ventures
  • Ken LaMontagne, VP, Research – Leukemia & Lymphoma Society (LLS)
  • William Werkmeister, Partner, ICIF Fund – National Foundation for Cancer Research
  • Cynthia Ringo, Managing Partner – DBL Partners